Edward Hodgkin
Partner @ Syncona Partners LLP
London, United Kingdom
Edward Hodgkin is a Series A investor at Syncona Partners LLP in London focused on Life Science and Pharmaceutical. Ed is a Partner of Syncona Partners LLP. Previously, he was Chief Executive Officer of Biotica Technology Ltd. Prior to joining Biotica in 2007, Ed spent 12 years in the US, serving as President & Chief Business Officer of BrainCells, Inc. (San Diego, CA) and Vice President, Business Development & Marketing at Tripos Inc. (St. Louis, MO).He has broad deal-making experience, including licensing, strategic alliances, company formation, equity financing and dispute resolution. His early career was spent in scientific and management roles at Wyeth-Ayerst, Inc. (Princeton, NJ) and British Biotech Ltd. (Oxford). Ed holds an MA and DPhil in Chemistry from Oxford University. He is a non-executive director of the BioIndustry Association. - See more at: http://www.synconapartners.com/team/#sthash.6s8At9HK.dpuf
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Edward Hodgkin invests in
Stages Edward Hodgkin invests in
Countries Edward Hodgkin invests in
Investment Focus
Industry
- Life Science 3 (38%)
- Pharmaceutical 2 (25%)
- Biopharma 1 (13%)
- Biotechnology 1 (13%)
Stage
- Series A 3 (38%)
- Series B 3 (38%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Resolution Therapeutics
|
Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases. | $28.9M / Series B / Oct 03, 2024 | |
OMass Technologies
|
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $98.9M / Series B / Apr 27, 2022 | |
OMass Therapeutics
|
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $94.7M / Series B / Apr 27, 2022 | |
|
Resolution Therapeutics
|
Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases. | $13.1M / Series A / Apr 05, 2022 | |
|
Resolution Therapeutics
|
Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases. | $34.8M / Series A / Dec 02, 2020 | |
|
OMass Technologies
|
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $36M / Series A / Feb 17, 2020 | |
|
OMass Therapeutics
|
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $35.8M / Series A / Feb 17, 2020 | |
|
OMass Technologies
|
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $18.3M / Series A / Nov 21, 2018 |
Co-Investors
About Syncona Partners LLP
Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Their vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.They seek to partner with the best, brightest and most ambitious minds in scienceto build globally competitive businesses. They take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. They focus on delivering dramatic efficacy for patients in areas of high unmet need.Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in their business. They make a donation of 0.3% of Net Asset Value to a range of charities each year.
Syncona Partners LLP Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Edward Hodgkin
Partner
|
|||
Magdalena Jonikas
Partner
|
|||
Chris Hollowood
Chief Investment Officer
|
|||
Chris Hollowood
Chief Investment Officer
|
|||
Christian Groendahl
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Edward Hodgkin invest in?
Edward Hodgkin invests primarily in Life Science, Pharmaceutical and Biopharma startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Edward Hodgkin last invest?
The most recent investment recorded for Edward Hodgkin closed in Oct 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
